Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Moodys
McKesson
Medtronic

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Rebastinib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Rebastinib: Patents, clinical trial progress, indications

Rebastinib is an investigational drug.

There have been 4 clinical trials for Rebastinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 20th 2018.

The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, Montefiore Medical Center, and Albert Einstein College of Medicine of Yeshiva University.

There are five US patents protecting this investigational drug and thirty-two international patents.

Recent Clinical Trials for Rebastinib
TitleSponsorPhase
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerAlbert Einstein College of Medicine of Yeshiva UniversityPhase 1

See all Rebastinib clinical trials

Clinical Trial Summary for Rebastinib

Top disease conditions for Rebastinib
Top clinical trial sponsors for Rebastinib

See all Rebastinib clinical trials

US Patents for Rebastinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rebastinib   See Pricing Inhibitors of BCR-ABL mutants and use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI)   See Pricing
Rebastinib   See Pricing Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC (Lawrence, KS)   See Pricing
Rebastinib   See Pricing Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC (Lawrence, KS)   See Pricing
Rebastinib   See Pricing Methods for inhibiting tie-2 kinase useful in the treatment of cancer Deciphera Pharmaceuticals, LLC (Lawrence, KS)   See Pricing
Rebastinib   See Pricing Proteolysis targeting chimera compounds and methods of preparing and using same Yale University (New Haven, CT)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rebastinib

Drugname Country Document Number Estimated Expiration Related US Patent
Rebastinib European Patent Office 3503888 2036-08-25   See Pricing
Rebastinib World Intellectual Property Organization (WIPO) 2018039467 2036-08-25   See Pricing
Rebastinib Australia 2007307679 2026-10-11   See Pricing
Rebastinib Brazil PI0719195 2026-10-11   See Pricing
Rebastinib Canada 2666563 2026-10-11   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Mallinckrodt
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.